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Over recent years the measurement of plasma oestrogen
levels, particularly oestradiol levels, in postmenopausal
women has made important contributions to an improved
understanding of the aetiology and treatment of breast
cancer. Current studies aim to build on this by determining
whether such measurements can be usefully incorporated
into the evaluation of breast cancer risk in relation to the
implementation of risk reduction strategies.
Plasma oestradiol analysis has also provided a key
pharmacodynamic endpoint in the development of inhibitors
of aromatase, the enzyme responsible for oestrogen
synthesis [1]. These drugs are now recognised as the most
effective endocrine agents in postmenopausal breast
cancer and are becoming ever more widely used [2].
Studies of the effects of these agents on other body
systems and how this relates to oestrogen suppression and
the measurement of compliance with aromatase inhibitor
treatment require further analysis of oestrogen levels.
Accurate assessment of plasma oestradiol levels is,
however, not straightforward. This is most particularly the
case in postmenopausal women where the mean
untreated levels are approximately 25 pmol/l (7 pg/ml).
The problems associated with accurate assessment are,
unfortunately, ill-understood and they may lead to
erroneous conclusions being made in research studies
and routine evaluation in the clinic if inappropriate assays
are conducted.
The assessment of oestradiol has until recently not been an
important issue in postmenopausal women other than in
research laboratories, but it has been essential for the
assessment of infertility and of strategies for ovulation
induction. Analytical methodologies have thus focused on
supplying results in the range of 100–1200 pmol/l as found
in normal premenopausal women, or higher still as found
during ovulation induction. The estimation of these levels is
far less demanding than those in postmenopausal women.
Compromises in the methodologies have thus been
possible that allow simplicity, automation, precision, the use
of small sample volumes and a rapid turn-round. These may
generate substantially inaccurate results but in this context
this has little detrimental effect on decision-making.
The major compromise has been to conduct the
immunoassay on serum or plasma that has not been
subject to pretreatments that extract the oestradiol from
the sample (e.g. with an organic extractant such as diethyl
ether). Extraction of this type was universally employed in
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Abstract
The determination of plasma oestradiol has numerous applications in epidemiology, reproductive
medicine and breast cancer management. Commercially available analytical methods, which measure
the hormone levels without prior purification, have been successfully developed for measuring
oestradiol in premenopausal women. The application of these methodologies to the quantification of
the very low levels of oestradiol in postmenopausal women is more problematic in terms of accuracy
and interpretation. The importance of using appropriate methodology is discussed and illustrated with
data demonstrating the disparity in the results obtained when low levels of oestradiol were quantified
using direct and indirect methods.
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the assay of oestradiol (and other plasma steroids) until
about 15 years ago and this allowed the analyte to be
quantified in a purified form. The application of the newer,
so-called direct analytical approaches to the assessment
of postmenopausal oestradiol levels can lead to gross and
misleading inaccuracies.
The immunoassay is universally used in the routine
laboratory assessment of oestradiol. The inaccuracies
result largely from two aspects of the immunoassay’s
application. First, oestradiol binds avidly (association
constant, 0.68 × 109 l/mol) to sex hormone binding
globulin such that, if antiserum is added directly to plasma
samples, the sex hormone binding globulin effectively
competes with the antibody for oestradiol. The direct
assays attempt to rectify this by adding displacing agents
to the analytical reagents. The second problem is the
presence in the blood of very high concentrations of
water-soluble conjugated steroids, at concentrations that
are orders of magnitude above those of oestradiol. These
may cross-react to a minor degree with the oestradiol
antiserum but their concentration and the sum effect of
numerous such compounds can lead to substantial
biases. General issues of the matrix of plasma that differ
between samples and can only be approximated in assay
standards also contribute to error.
An overview study by the Endogenous Hormones and
Breast Cancer Collaborative Group of prospective
collections of plasma and subsequent measurements of
oestradiol and associated steroids in women that
eventually developed breast cancer illustrates both the
importance of plasma oestradiol in postmenopausal
women and the inaccuracies of analysis [3]. Inconsistent
results had been published on the relationship between
plasma oestradiol levels and breast cancer risk, but this
overview analysis of nine studies revealed a highly
significant relationship (Fig. 1) in which there was an
overall increase in relative risk of 1.29 (95% confidence
interval, 1.15–1.44; P < 0.001) for every doubling of
oestradiol concentration. The true risk is probably higher
since the measurements were made on single samples
and it has been estimated that taking account of within-
subject variability by taking multiple samples may lead to a
doubling of estimates of relative risk [4]. The problems in
analysis are illustrated by the mean oestradiol levels in the
postmenopausal controls reported by the various
laboratories varying about fivefold, and ranging from
21.7 pmol/l to 101 pmol/l. Four of the nine studies used
different direct radioimmunoassays and the other five
studies used an organic extraction prior to radioimmuno-
assay. Quoted detection limits ranged in value from
3 pmol/l to 37 pmol/l.
The way in which the performance of most direct assays
varies from the performance of an assay that uses organic
extraction, and has been sensitised and validated for use
in postmenopausal women, is vividly demonstrated by the
comparisons made in Fig. 2. Each panel in Fig. 2
demonstrates the results obtained when pairs of samples
taken from 10 postmenopausal breast cancer patients
were analysed for oestradiol using four different methods.
For each patient the first sample was taken before, and
the second sample during, the use of anastrozole, an
aromatase inhibitor. Anastrozole inhibits aromatase, the
sole source of steroidal oestrogens, by a mean 97% [5].
However, in Fig. 2a (Estradiol 33540; Beckman Coulter
Access Immunoassay system, Fullerton, CA, USA) and in
Fig. 2b (3rd Generation Estradiol Radioimmunoassay,
DSL-39100; Diagnostic Systems Laboratories Inc.,
Webster, TX, USA) the application of two types of direct
assays gives values that fall by a mean 25% and 34%,
respectively, and in some cases patients show no
suppression in oestradiol levels at all. This observation
contrasts markedly with the situation in Fig. 2c, which
shows the results from applying a sensitive extraction
assay [6]. All these patients show almost complete
suppression of oestradiol levels, mostly to below the
sensitivity limit of the assay (3 pmol/l). By designating
samples with values below the detection limit as having
values of 3 pmol/l a mean suppression of 88% may be
calculated, but this is inevitably an underestimate.
Revealingly, the application of an extraction step prior to
use of the DSL-39100 kit (used in its normal direct
fashion in Fig. 2b) leads to results that now resemble
those derived from the extraction assay.
There were significant correlations between the
pretreatment results obtained with the sensitive extraction
assay and those obtained with the other three assays:
Figure 1
Relative risk (RR) of breast cancer by increasing quintiles of oestradiol
concentration from a pooled analysis of nine studies (modified from
[3]). The position of each square indicates the magnitude of the RR,
and the area of the square is proportional to the amount of statistical
information available. The length of the horizontal line through the
square indicates the 95% confidence interval (CI).
Quintile RR and 95% CI χ2 χ21  for trend
1
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3 22.26
4 P < 0.001
5
0.5          1                 2                  43
r = 0.51 for the DSL-39100 kit, r = 0.73 for the Beckman
Coulter Access 33540 and r = 0.98 for the DSL-39100
kit after organic extraction.
The results of the present study with the aromatase
inhibitor suggest that at least 70% of the oestradiol
measured by the two direct assays in postmenopausal
women is an artifact. These assays are probably no worse
in this respect than other direct immunoassays, and may in
fact be better. It should particularly be noted that the
Beckman method has a detection limit of 73 pmol/l and
that values below this level should be quoted as <73
pmol/l. The results indicate that the use of direct assays to
check compliance of women on aromatase inhibitors or to
conduct research studies in postmenopausal women is
inappropriate and is likely to give aberrant guidance. Such
assays are also not suitable to help distinguish post-
menopausal women from premenopausal women; this is
occasionally necessary in tamoxifen-treated patients
where confounding effects of the drug on gonadotropin
levels make these levels unsuitable for the determination
of menopausal status.
This variability between methodological approaches
obviously did not prevent the Endogenous Hormones and
Breast Cancer Collaborative Group from making the very
valuable epidemiological observation of the relationship
between plasma oestradiol levels and breast cancer risk.
Indeed, these methods may be considered satisfactory for
some epidemiological purposes where limitations of sample
volume may be a major consideration. The methodological
limitations almost certainly affected their ability to define
accurately the strength of the relationship, however, and will
continue to do so if implemented in future studies.
Available online http://breast-cancer-research.com/content/7/1/1
Figure 2
Each panel shows the results of analysing pairs of samples from 10 postmenopausal breast cancer patients. Light column, measured serum
oestradiol before treatment (Pre); dark column, result during the use of the aromatase inhibitor, anastrozole. (a), (b) Results obtained when the
oestradiol was measured by direct assay: (a) Beckman Coulter Access Immumoassay system Estradiol 33540, and (b) DSL 3rd Generation
Estradiol Radioimmunoassay DSL-39100. (c), (d) Results when the oestradiol is measured after a pre-extraction with an organic solvent: (c)
extraction and radioimmunoassay (as used at the Royal Marsden [6]), and (d) the DSL-39100 kit after pre-extraction of serum samples with diethyl
ether. Arrows indicate the detection limits for the assays; no arrow in (d) since this analysis was performed for the present study only and no
detection limit was determined.
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(b)                      DSL-39100 kit
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(c)                    Sensitive extraction method
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(d)               DSL-39100 after ether extraction
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A number of investigators now view this relationship
between plasma oestradiol levels and breast cancer risk
as one that has important potential for inclusion in
algorithms for predicting breast cancer risk, particularly in
association with antihormonal strategies for breast cancer
prevention [7]. The implementation of such an approach
will require the use of accurate, well-validated, rugged
assays that operate alongside well-developed risk
relationships for different populations. It is possible that
new, more definitive nonimmunoassay approaches to the
oestradiol assay (e.g. with tandem mass spectrometry)
may allow accurate and precise assay of oestradiol [8].
However, when immunoassays are applied it seems
inevitable that we will have to employ labour-intensive and
inconvenient extraction procedures for the accurate
analysis that these new opportunities demand.
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